Phenotypes selected during chronic lung infection in cystic fibrosis patients: Implications for the treatment of Pseudomonas aeruginosa biofilm infections

FEMS Immunology and Medical Microbiology

Volumn 65, Issue 2, 2012, Pages 215-225

  Ciofu, Oana ^a   Mandsberg, Lotte F ^a   Wang, Hengzhuang ^b   Høiby, Niels ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Antibiotic tolerance; Beta lactamase; Biofilm; Hypermutability; Mucoidy; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CIPROFLOXACIN; COLISTIN; IMIPENEM; MACROLIDE; PIPERACILLIN PLUS TAZOBACTAM; REACTIVE OXYGEN METABOLITE; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC TOLERANCE; BACTERIAL MUTATION; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOFILM; CHRONIC LUNG INFECTION; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG TOLERANCE; EFFUSION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; MISMATCH REPAIR; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUORUM SENSING; SHORT SURVEY; SPUTUM CULTURE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; BIOFILMS; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; LUNG; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SELECTION, GENETIC;

EID: 84862671814     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2012.00983.x     Document Type: Short Survey

References (86)

1. Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M & Hoiby N (2002) Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother 46: 3406-3411.
2. Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, Greenberg EP & Hoiby N (2004) Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob Agents Chemother 48: 1175-1187.
3. Bjarnsholt T, Jensen PO, Burmolle M et al. (2005) Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 151: 373-383.
4. Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M & Hoiby N (2009) Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 44: 547-558.
5. Boles BR & Singh PK (2008) Endogenous oxidative stress produces diversity and adaptability in biofilm communities. P Natl Acad Sci USA 105: 12503-12508.
6. Chiang WC, Pamp SJ, Nilsson M, Givskov M & Tolker-Nielsen T (2012) The metabolically active subpopulation in Pseudomonas aeruginosa biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms. FEMS Immunol Med Microbiol. doi: 10.1111/j.1574-695X.2012.00929.x. [Epub ahead of print].
7. Ciofu O (2003) Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. APMIS 111: 1-47.
8. Ciofu O & Høiby N (2007) Cystic fibrosis-coping with resistance. Antibiotic Policies: Fighting Resistance (Gould IM & van der Meer J, eds), pp. 149-174. Springer, Berlin.
9. Ciofu O & Tolker-Nielsen T (2011) Antibiotic tolerance and resistance in biofilms. Biofilm Infections (Bjarnsholt T, Moser C, Jensen PO & Høiby N, eds), pp. 215-229. Springer, Berlin.
10. Ciofu O, Giwercman B, Pedersen SS & Hoiby N (1994) Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. Apmis 102: 674-680.
11. Ciofu O, Beveridge TJ, Kadurugamuwa J, Walther-Rasmussen J & Hoiby N (2000) Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J Antimicrob Chemother 45: 9-13.
12. Ciofu O, Fussing V, Bagge N, Koch C & Hoiby N (2001) Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother 48: 391-396.
13. Ciofu O, Riis B, Pressler T, Poulsen HE & Hoiby N (2005) Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 49: 2276-2282.
14. Ciofu O, Mandsberg LF, Bjarnsholt T, Wassermann T & Hoiby N (2010) Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 156: 1108-1119.
15. Conibear TC, Collins SL & Webb JS (2009) Role of mutation in Pseudomonas aeruginosa biofilm development. PLoS ONE 4: e6289.
16. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1-10.
17. De Kievit TR, Parkins MD, Gillis RJ, Srikumar R, Ceri H, Poole K, Iglewski BH & Storey DG (2001) Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 45: 1761-1770.
18. Doggett RG (1969) Incidence of mucoid Pseudomonas aeruginosa from clinical sources. Appl Microbiol 18: 936-937.
19. Doring G & Hoiby N (2004) Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 3: 67-91.
20. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A & Touw DJ (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16: 749-767.
21. Driffield K, Miller K, Bostock JM, O'Neill AJ & Chopra I (2008) Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother 61: 1053-1056.
22. Frederiksen B, Koch C & Hoiby N (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23: 330-335.
23. Fux CA, Costerton JW, Stewart PS & Stoodley P (2005) Survival strategies of infectious biofilms. Trends Microbiol 13: 34-40.
24. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS & Conrad DJ (2011) Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 183: 1510-1516.
25. Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP & Iglewski BH (2005) Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 49: 3858-3867.
26. Giwercman B, Lambert PA, Rosdahl VT, Shand GH & Hoiby N (1990) Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. J Antimicrob Chemother 26: 247-259.
27. Giwercman B, Meyer C, Lambert PA, Reinert C & Hoiby N (1992) High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob Agents Chemother 36: 71-76.
28. Haagensen JA, Klausen M, Ernst RK, Miller SI, Folkesson A, Tolker-Nielsen T & Molin S (2007) Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 189: 28-37.
29. Hansen CR, Pressler T, Koch C & Hoiby N (2005) Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 4: 35-40.
30. Hansen CR, Pressler T & Hoiby N (2008) Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 7: 523-530.
31. Hassett DJ, Korfhagen TR, Irvin RT, Schurr MJ, Sauer K, Lau GW, Sutton MD, Yu H & Hoiby N (2010) Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets 14: 117-130.
32. Heijerman H, Westerman E, Conway S, Touw D & Doring G (2009) Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 8: 295-315.
33. Hengzhuang W, Wu H, Ciofu O, Song Z & Hoiby N (2011) Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 55: 4469-4474.
34. Hengzhuang W, Wu H, Ciofu O, Song Z & Hoiby N (2012) In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem on biofilm Pseudomonas aeruginosa. Antimicrob Agents Chemother 56: 2683-2690.
35. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M & Parsek MR (2001) Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 183: 5395-5401.
36. Herrmann G, Yang L, Wu H, Song Z, Wang H, Hoiby N, Ulrich M, Molin S, Riethmuller J & Doring G (2010) Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 202: 1585-1592.
37. Hill D, Rose B, Pajkos A et al. (2005) Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 43: 5085-5090.
38. Hoffman LR, D'Argenio DA, MacCoss MJ, Zhang Z, Jones RA & Miller SI (2005) Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436: 1171-1175.
39. Hoiby N (1977) Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 262: 1-96.
40. Hoiby N (2011) Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 9: 32.
41. Hoiby N, Bjarnsholt T, Givskov M, Molin S & Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35: 322-332.
42. Islam S, Oh H, Jalal S, Karpati F, Ciofu O, Hoiby N & Wretlind B (2009) Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect 15: 60-66.
43. Jalal S, Ciofu O, Hoiby N, Gotoh N & Wretlind B (2000) Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 44: 710-712.
44. Jensen T, Pedersen SS, Hoiby N, Koch C & Flensborg EW (1989) Use of antibiotics in cystic fibrosis. The Danish approach. Antibiot Chemother 42: 237-246.
45. Johansen HK, Moskowitz SM, Ciofu O, Pressler T & Hoiby N (2008) Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 7: 391-397.
46. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA & Collins JJ (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130: 797-810.
47. Kolpen M, Hansen CR, Bjarnsholt T et al. (2010) Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 65: 57-62.
48. Kvist M, Hancock V & Klemm P (2008) Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol 74: 7376-7382.
49. Lee B, Haagensen JA, Ciofu O, Andersen JB, Hoiby N & Molin S (2005) Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol 43: 5247-5255.
50. Lee B, Schjerling CK, Kirkby N, Hoffmann N, Borup R, Molin S, Hoiby N & Ciofu O (2011) Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. Apmis 119: 263-274.
51. Ma L, Wang S, Wang D, Parsek MR & Wozniak DJ (2012) The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms. FEMS Immunol Med Microbiol doi: 10.1111/j.1574-695X.2012.00934.x. [Epub ahead of print].
52. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL & Oliver A (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49: 3382-3386.
53. Macia MD, Borrell N, Segura M, Gomez C, Perez JL & Oliver A (2006) Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother 50: 975-983.
54. Macia MD, Perez JL, Molin S & Oliver A (2011) Dynamics of mutator and antibiotic resistant populations in a pharmacokinetic/pharmacodynamic (PK/PD) model of Pseudomonas aeruginosa biofilms treatment. Antimicrob Agents Chemother 55: 5230-5237.
55. Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE & Hoiby N (2009) Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother 53: 2483-2491.
56. Mandsberg LF, Macia MD, Bergmann KR, Christiansen LE, Alhede M, Kirkby N, Hoiby N, Oliver A & Ciofu O (2011) Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM). FEMS Microbiol Lett 324: 28-37.
57. Mathee K, Ciofu O, Sternberg C et al. (1999) Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145: 1349-1357.
58. Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U & Ramsey BW (2012) Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 47: 125-134.
59. Moriarty TF, McElnay JC, Elborn JS & Tunney MM (2007) Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 42: 1008-1017.
60. Moskowitz SM, Foster JM, Emerson J & Burns JL (2004) Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42: 1915-1922.
61. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, Brockhurst MA & Winstanley C (2011) Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am J Respir Crit Care Med 183: 1674-1679.
62. Mulet X, Moya B, Juan C, Macia MD, Perez JL, Blazquez J & Oliver A (2011) Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. Antimicrob Agents Chemother 55: 4560-4568.
63. Nichols WW, Evans MJ, Slack MP & Walmsley HL (1989) The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol 135: 1291-1303.
64. Nivens DE, Ohman DE, Williams J & Franklin MJ (2001) Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms. J Bacteriol 183: 1047-1057.
65. Oliver A, Canton R, Campo P, Baquero F & Blazquez J (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288: 1251-1254.
66. Oliver A, Sanchez JM & Blazquez J (2002) Characterization of the GO system of Pseudomonas aeruginosa. FEMS Microbiol Lett 217: 31-35.
67. Pamp SJ, Gjermansen M, Johansen HK & Tolker-Nielsen T (2008) Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 68: 223-240.
68. Pedersen SS, Hoiby N, Espersen F & Koch C (1992) Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 47: 6-13.
69. Poole K (2008) Bacterial Multidrug Efflux Pumps Serve Other Functions.Microbe 3: 179-185.
70. Prescott WA Jr, Gentile AE, Nagel JL & Pettit RS (2011) Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. Pharmacy and Therapeutics (P&T) 36: 723-763.
71. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van KS & Grasemann H (2006) Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57: 306-311.
72. Ratjen F, Brockhaus F & Angyalosi G (2009) Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 8: 361-369.
73. Rau MH, Hansen SK, Johansen HK, Thomsen LE, Workman CT, Nielsen KF, Jelsbak L, Hoiby N, Yang L & Molin S (2010) Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ Microbiol 12: 1643-1658.
74. Safdar N, Andes D & Craig WA (2004) In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48: 63-68.
75. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ & Campbell PW III (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290: 1749-1756.
76. Stewart PS (1996) Theoretical aspects of antibiotic diffusion into microbial biofilms. Antimicrob Agents Chemother 40: 2517-2522.
77. Taccetti G, Campana S, Festini F, Mascherini M & Doring G (2005) Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 26: 458-461.
78. Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F, Zavataro L & Campana S (2012) Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax doi: 10.1136/thoraxjnl-2011-200832.
79. Takahashi A, Yomoda S, Ushijima Y, Kobayashi I & Inoue M (1995) Ofloxacin, norfloxacin and ceftazidime increase the production of alginate and promote the formation of biofilm of Pseudomonas aeruginosa in vitro. J Antimicrob Chemother 36: 743-745.
80. Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S & Montgomery AB (2011) Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros 10: 234-242.
81. Whitchurch CB, Tolker-Nielsen T, Ragas PC & Mattick JS (2002) Extracellular DNA required for bacterial biofilm formation. Science 295: 1487.
82. Williamson KS, Richards LA, Perez-Osorio AC, Pitts B, McInnerney K, Stewart PS & Franklin MJ (2012) Heterogeneity in Pseudomonas aeruginosa biofilms includes expression of ribosome hibernation factors in the antibiotic tolerant subpopulation and hypoxia induced stress response in the metabolically active population. J Bacteriol 194: 2062-2073.
83. Worlitzsch D, Tarran R, Ulrich M et al. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109: 317-325.
84. Yang L, Haagensen JA, Jelsbak L, Johansen HK, Sternberg C, Hoiby N & Molin S (2008) In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol 190: 2767-2776.
85. Yang Y, Tsifansky MD, Wu CJ, Yang HI, Schmidt G & Yeo Y (2010) Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res 27: 151-160.
86. Yang L, Jelsbak L, Marvig RL et al. (2011) Evolutionary dynamics of bacteria in a human host environment. P Natl Acad Sci USA 108: 7481-7486.